Basic Information

Gene symbol VEGFA Synonyms L-VEGF, MVCD1, VEGF, VPF Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description vascular endothelial growth factor A

GTO ID GTC0130
Trial ID NCT01486238
Disease Diabetic Macular Edema
Altered gene VEGFA
Therapeutic/Target gene Target gene
TherapyAptamer
Treatment Macugen|pegaptanib|EYE001
PhasePhase4
Recruitment statusCompleted
TitlePegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study
Year2009
CountryUnited States
Company sponsorValley Retina Institute
Other ID(s)PRESERVE

Clinical Result

Cohort1: 4 injections
Administration route intravitreal injection
Dosage Macugen, 0.3 mg, 4 injections, 6 week intervals beginning on Day 0 and ending at Week 18
Pts 23
Age Adult, Older_Adult
Outcome Proportion of Subjects Who Gain Two or More Lines in Best Corrected Visual Acuity(BCVA) Score in the Study Eye Compared With Baseline:Measure Type: Number:3
Adverse reactions 3/23(Eye disorders; Gastrointestinal disorders; Hepatobiliary disorders; Skin and subcutaneous tissue disorders)
Cohort2: 6 injections
Administration route intravitreal injection
Dosage Macugen, 0.3 mg, 6 injections, 4 week intervals beginning on Day 0 and ending at Week 20
Pts 49
Age Adult, Older_Adult
Outcome Proportion of Subjects Who Gain Two or More Lines in Best Corrected Visual Acuity(BCVA) Score in the Study Eye Compared With Baseline:Measure Type: Number:18
Adverse reactions 12/49(Blood and lymphatic system disorders; Cardiac disorders; Endocrine disorders; Eye disorders; Gastrointestinal disorders; Musculoskeletal and connective tissue disorders; Respiratory, thoracic and mediastinal disorders; Skin and subcutaneous tissue disorders)

Relationship Graph

Overview of Knowledge Graph